drugset / Trial / NCT01137123

Improve the Treatment of Thoracic Esophageal Cancer

NCT01137123

Phase 3 Completed 301 enrolled Sun Yat-sen University
RandomizedFactorialSingle-blindTreatment

Summary

The purpose of this study is 1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on the staging and prognosis of resectable esophageal cancer, which defined by the International Association of esophageal disease(ISDE) - standard mediastinal lymphadenectomy,total mediastinal lymphadenectomy and three field lymphadenectomy,and to find out reasonable range of lymphadenectomy. 2. To compare the effects of Chemotherapy Group (Docetaxel + Nedaplatin) with Control Group on the prognosis of resectable thoracic esophageal cancer,and to explore the indications of adjuvant chemotherapy.

Timeline

Start
2010-04
Primary completion
2020-12
Completion
2020-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Nedaplatin Small molecule 75 mg/m2 Intravenous